EB-003

EB-003 is a novel, non-hallucinogenic, neuroplastogenic small molecule developed by Enveric Biosciences for the treatment of psychiatric and neurological disorders such as major depressive disorder and anxiety disorders. It is an indolethylamine (tryptamine) derivative that acts as an oral agent exhibiting significant brain penetration and neuroplasticity-promoting effects, modeled to reduce or eliminate hallucinogenic side effects typical of psychedelics like DMT. EB-003 is distinct in its dual mechanism of action as a serotonin 5-HT1B receptor agonist and 5-HT2A receptor partial agonist, a profile believed to drive efficacy in mood disorders while maintaining a strong safety and tolerability profile, as demonstrated in preclinical rodent models. The drug is currently in preclinical development, with plans to initiate first-in-human studies focusing on severe depression and anxiety disorders[1][2][3][4][5][6][7].

Other names

EB-003EB003EB 003